EU Draft Merger Guidelines: Capabilities Treatment Needs Revisiting

EU Draft Merger Guidelines: Capabilities Treatment Needs Revisiting

The European Commission's draft merger guidelines shift focus to "capabilities," assessing how firms compete and pivot to future markets. This article examines the implications for pharmaceutical mergers and acquisitions, offering a practical guide for business development and M&A teams navigating the most significant overhaul of EU merger control in two decades. The new merger guidelines represent a critical development for the industry.

IntelligenceRegulatory Impact▾

European Commission are the bodies to watch. Regulatory relevance reads medium for this therapeutic area. Teams should track submission types, designations, and any guidance shifts that could move approval timelines.

Key Takeaways

• The European Commission's draft merger guidelines reorient analysis around "capabilities"—how firms compete today and their ability to pivot to future markets, marking a departure from the traditional focus on market shares and concentration levels.
• The guidelines expand merger scrutiny to cover labour markets, non-controlling minority shareholdings, and common ownership, reflecting a broader view of potential competitive harm.
• Efficiency claims must be verifiable and quantifiable, with flexibility where appropriate, requiring pharma teams to prepare detailed evidence on how a merger enhances capabilities without harming competition.
• Pharmaceutical M&A teams should prepare for increased regulatory scrutiny of deals involving platform technologies, pipeline assets in adjacent therapeutic areas, and transactions affecting specialized talent pools.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

What Changed in the EU Merger Guidelines?

The European Commission published its draft merger guidelines in June 2026, representing the most significant overhaul of EU merger control in two decades. The guidelines reorient merger analysis around "capabilities," assessing how firms compete in current markets and their ability to pivot to future ones. This marks a departure from the previous focus on market shares and concentration levels, which had been the bedrock of EU merger review since the 2004 Horizontal Merger Guidelines.

The draft also extends merger scrutiny to cover labour markets, non-controlling minority shareholdings, and common ownership, reflecting a broader view of potential competitive harm. The Commission has signaled that it will now assess whether a merger grants the combined entity excessive buyer power over specialized labor pools, a significant shift for knowledge-intensive industries like pharma. The guidelines require that any efficiency claimed to arise from the merger must be verifiable and quantifiable with flexibility where appropriate, according to the draft guidelines document.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for this therapeutic area pricing, access, and launch sequencing.

How Will the New Guidelines Affect Pharma M&A?

For pharmaceutical business development and M&A teams, the new guidelines introduce significant uncertainty. Deals involving platform technologies—such as gene editing, mRNA, and antibody-drug conjugates—or pipeline assets in adjacent therapeutic areas may now face heightened scrutiny, as regulators assess whether the merged entity would have the capability to foreclose rivals or reduce innovation. The ProMarket analysis of the guidelines notes that the treatment of capabilities needs revisiting, arguing that the framework risks capturing too many benign transactions while missing genuinely anticompetitive ones.

Teams should prepare to provide detailed evidence on how a merger enhances capabilities without harming competition, including verifiable and quantifiable efficiency claims. The expanded focus on labour markets also means that deals affecting specialized talent pools—such as rare disease researchers or cell therapy engineers—could be challenged on monopsony grounds. This represents a new front in pharma M&A risk assessment that deal teams have not historically needed to model.

The guidelines also introduce explicit treatment of non-controlling minority shareholdings and common ownership, which could affect the structure of venture investments and licensing deals that pharma companies routinely use to access external innovation. Dealmakers should review existing minority stakes and common ownership positions for potential exposure under the new framework.

Frequently Asked Questions

Related coverage

• WHO Revised Biosimilar Guidelines: Streamlined Regulation for Improved Global Access